Amplia announces ovarian cancer study with ANZGOG

Amplia has announced a new clinical collaboration with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to evaluate narmafotinib in ovarian cancer.

The investigator-initiated study will assess narmafotinib, Amplia’s best-in-class FAK inhibitor, in combination with standard chemotherapy (carboplatin and paclitaxel) in patients with high-grade serous ovarian cancer (HGSOC) who have not responded to platinum-based chemotherapy prior to surgery.

Approximately one in five ovarian cancer patients do not respond adequately to initial chemotherapy, limiting surgical options and contributing to poor outcomes. The study will therefore also explore whether the addition of narmafotinib can increase the proportion of patients eligible for successful surgical resection.

Amplia CEO and MD, Dr Chris Burns, commented:

“We are very pleased to be collaborating with ANZGOG and Dr Ho on this important study. Based on the compelling biological rationale for FAK inhibitors’ potential in ovarian cancer, a clinical program in this indication is clearly warranted. Patients with ovarian cancer who do not respond to initial chemotherapy have very limited treatment options. This study will provide an opportunity to assess whether narmafotinib can improve outcomes for these patients and represents an important step in broadening the clinical utility of our FAK inhibitor program.”

Click to read the ASX announcement.